ЖурналыПодпискаАрхивКнигиПроектыО насРекламаДоставка/ОплатаКонтакты
+7 (495) 482-43-29
  • Главная
  • / Журналы
  • / Вернуться в журнал
  • / Содержание номера
  • / Статья
Мы и МАБы

Мы и МАБы

Авторы:
Княжеская Н.П.,
Анаев Э.Х.,
Белевский А.С.,
Мещерякова Н.Н.

Журнал: Non nocere. Новый терапевтический журнал. 2025;(10):76-81.

Прочитано: 423 раза

Резюме

Генно-инженерные биологические препараты в лечении бронхиальной астмы: что нужно знать врачам общей практики и терапевтам первичного звена.

Дата публикации: 18.11.2025

Литература / References
  1. Skloot GS. Asthma phenotypes and endotypes: a personalized approach to treatment. Curr Opin Pulm Med. 2016 Jan;22(1):3-9. https://doi.org/10.1097/MCP.0000000000000225
  2. Global Initiative for Asthma. Global Strategy for Asthma Management and Prevention, 2024. Last updated: May 2024 [Electronic resource]. Access date: May 14, 2024. https://ginasthma.org/wp-content/uploads/2024/05/GINA-2024-Main-Report-WMS-1.pdf
  3. Chung KF, Wenzel SE, Brozek JL, et al. International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma. Eur Respir J. 2014 Feb;43(2):343-373. https://doi.org/10.1183/09031936.00202013
  4. Bousquet J, Mantzouranis E, Cruz AA, et al. Uniform definition of asthma severity, control, and exacerbations: document presented for the World Health Organization Consultation on Severe Asthma. J Allergy Clin Immunol. 2010 Nov;126(5):926-938. https://doi.org/10.1016/j.jaci.2010.07.019
  5. Chung KF. Managing severe asthma in adults: lessons from the ERS/ATS guidelines. Curr Opin Pulm Med. 2015 Jan;21(1):8-15. https://doi.org/10.1097/MCP.0000000000000116
  6. Mansur AH, Prasad N. Management of difficult-to-treat asthma in adolescence and young adults. Breathe (Sheff). 2023 Mar;19(1):220025. https://doi.org/10.1183/20734735.0025-2022
  7. Lloyd CM, Robinson DS. Allergen-induced airway remodelling. Eur Respir J. 2007 May;29(5):1020-1032. https://doi.org/10.1183/09031936.00150305
  8. Hylkema MN, Sterk PJ, de Boer WI, Postma DS. Tobacco use in relation to COPD and asthma. Eur Respir J. 2007 Mar;29(3):438-445. https://doi.org/10.1183/09031936.00124506
  9. Venancio-Hernández M, Mendieta-Flores E, Mendiola-Marín J, Alaniz-Flores AK, Reyes-Arellano M. Abordaje diagnóstico del asma difícil de tratar y asma grave [The diagnostic approach to difficult-to-treat asthma and severe asthma]. Rev Alerg Mex. 2022;69 Suppl 1:s94–s111. Spanish. https://doi.org/10.29262/ram.v69iSupl1.1046
  10. The ENFUMOSA cross-sectional European multicentre study of the clinical phenotype of chronic severe asthma. European Network for Understanding Mechanisms of Severe Asthma. Eur Respir J. 2003 Sep;22(3):470-477. https://doi.org/10.1183/09031936.03.00261903
  11. Tan R, Liew MF, Lim HF, Leung BP, Wong WSF. Promises and challenges of biologics for severe asthma. Biochem Pharmacol. 2020 Sep;179:114012. https://doi.org/10.1016/j.bcp.2020.114012
  12. Dahlén SE. Asthma phenotyping: noninvasive biomarkers suitable for bedside science are the next step to implement precision medicine. J Intern Med. 2016 Feb;279(2):205-207. https://doi.org/10.1111/joim.12466
  13. Hekking PW, Wener RR, Amelink M, Zwinderman AH, Bouvy ML, Bel EH. The prevalence of severe refractory asthma. J Allergy Clin Immunol. 2015 Apr;135(4):896-902. https://doi.org/10.1016/j.jaci.2014.08.042
  14. Agache I, Beltran J, Akdis C, et al. Efficacy and safety of treatment with biologicals (benralizumab, dupilumab, mepolizumab, omalizumab and reslizumab) for severe eosinophilic asthma. A systematic review for the EAACI Guidelines – recommendations on the use of biologicals in severe asthma. Allergy. 2020 May;75(5):1023-1042. https://doi.org/10.1111/all.14221
  15. Menzies-Gow A, Corren J, Bourdin A, et al. Tezepelumab in Adults and Adolescents with Severe, Uncontrolled Asthma. N Engl J Med. 2021 May 13;384(19):1800-1809. https://doi.org/10.1056/NEJMoa2034975
  16. Buhl R, Korn S, Menzies-Gow A, et al. Prospective, Single-Arm, Longitudinal Study of Biomarkers in Real-World Patients with Severe Asthma. J Allergy Clin Immunol Pract. 2020 Sep;8(8):2630-2639.e6. https://doi.org/10.1016/j.jaip.2020.03.038
  17. Tran TN, Zeiger RS, Peters SP, et al. Overlap of atopic, eosinophilic, and TH2-high asthma phenotypes in a general population with current asthma. Ann Allergy Asthma Immunol. 2016 Jan;116(1):37-42. https://doi.org/10.1016/j.anai.2015.10.027
  18. Djukanović R, Wilson SJ, Kraft M, et al. Effects of treatment with anti-immunoglobulin E antibody omalizumab on airway inflammation in allergic asthma. Am J Respir Crit Care Med. 2004 Sep 15;170(6):583-593. https://doi.org/10.1164/rccm.200312-1651OC
  19. Pan S, Conaway S Jr, Deshpande DA. Mitochondrial regulation of airway smooth muscle functions in health and pulmonary diseases. Arch Biochem Biophys. 2019 Mar 15;663:109-119. https://doi.org/10.1016/j.abb.2019.01.002
  20. Roth M, Zhao F, Zhong J, Lardinois D, Tamm M. Serum IgE Induced Airway Smooth Muscle Cell Remodeling Is Independent of Allergens and Is Prevented by Omalizumab. PLoS One. 2015 Sep 2;10(9):e0136549. https://doi.org/10.1371/journal.pone.0136549
  21. Vennera MDC, Sabadell C, Picado C; Spanish Omalizumab Registry. Duration of the efficacy of omalizumab after treatment discontinuation in ‘real life’ severe asthma. Thorax. 2018 Aug;73(8):782-784. https://doi.org/10.1136/thoraxjnl-2017-210017
  22. Baena-Cagnani CE, Teijeiro A, Canonica GW. Four-year follow-up in children with moderate/severe uncontrolled asthma after withdrawal of a 1-year omalizumab treatment. Curr Opin Allergy Clin Immunol. 2015 Jun;15(3):267-271. https://doi.org/10.1097/ACI.0000000000000161
  23. Kim DH, Park KY, Kim BJ, Kim MN, Mun SK. Anti-immunoglobulin E in the treatment of refractory atopic dermatitis. Clin Exp Dermatol. 2013 Jul;38(5):496-500. https://doi.org/10.1111/j.1365-2230.2012.04438.x
  24. Naclerio RM, Baroody FM, Pinto JM. Should clinicians use omalizumab for the treatment of nasal polyps? J Allergy Clin Immunol. 2013 Jul;132(1):247. https://doi.org/10.1016/j.jaci.2013.04.001
  25. Gevaert P, Calus L, Van Zele T, et al. Omalizumab is effective in allergic and nonallergic patients with nasal polyps and asthma. J Allergy Clin Immunol. 2013 Jan;131(1):110-116.e1. https://doi.org/10.1016/j.jaci.2012.07.047
  26. Agache I, Rocha C, Beltran J, et al. Efficacy and safety of treatment with biologicals (benralizumab, dupilumab and omalizumab) for severe allergic asthma: A systematic review for the EAACI Guidelines – recommendations on the use of biologicals in severe asthma. Allergy. 2020 May;75(5):1043-1057. https://doi.org/10.1111/all.14235
  27. Deeks ED, Brusselle G. Reslizumab in Eosinophilic Asthma: A Review. Drugs. 2017 May;77(7):777-784. https://doi.org/10.1007/s40265-017-0740-2
  28. Máspero J. Reslizumab in the treatment of inadequately controlled asthma in adults and adolescents with elevated blood eosinophils: clinical trial evidence and future prospects. Ther Adv Respir Dis. 2017 Aug;11(8):311-325. https://doi.org/10.1177/1753465817717134
  29. Albers FC, Price RG, Smith SG, Yancey SW. Mepolizumab efficacy in patients with severe eosinophilic asthma receiving different controller therapies. J Allergy Clin Immunol. 2017 Nov;140(5):1464-1466.e4. https://doi.org/10.1016/j.jaci.2017.06.010
  30. Caminati M, Cegolon L, Vianello A, et al. Mepolizumab for severe eosinophilic asthma: a real-world snapshot on clinical markers and timing of response. Expert Rev Respir Med. 2019 Dec;13(12):1205-1212. https://doi.org/10.1080/17476348.2019.1676734
  31. Bakakos A, Rovina N, Bakakos P. Treatment Challenges in Severe Eosinophilic Asthma: Differential Response to Anti-IL-5 and Anti-IL-5R Therapy. Int J Mol Sci. 2021 Apr 12;22(8):3969. https://doi.org/10.3390/ijms22083969
  32. Matera MG, Rogliani P, Calzetta L, Canonica GW, Cazzola M. Benralizumab for the treatment of asthma. Drugs Today (Barc). 2017 Dec;53(12):633-645. https://doi.org/10.1358/dot.2017.53.12.2736670
  33. Pelaia C, Busceti MT, Crimi C, et al. Real-Life effects of benralizumab on exacerbation number and lung hyperinflation in atopic patients with severe eosinophilic asthma. Biomed Pharmacother. 2020 Sep;129:110444. https://doi.org/10.1016/j.biopha.2020.110444
  34. Gavett SH, O’Hearn DJ, Karp CL, et al. Interleukin-4 receptor blockade prevents airway responses induced by antigen challenge in mice. Am J Physiol. 1997 Feb;272(2 Pt 1):L253-261. https://doi.org/10.1152/ajplung.1997.272.2.L253
  35. Rabe KF, Nair P, Brusselle G, et al. Efficacy and Safety of Dupilumab in Glucocorticoid-Dependent Severe Asthma. N Engl J Med. 2018 Jun 28;378(26):2475-2485. https://doi.org/10.1056/NEJMoa1804093
  36. Gour N, Wills-Karp M. IL-4 and IL-13 signaling in allergic airway disease. Cytokine. 2015 Sep;75(1):68-78. https://doi.org/10.1016/j.cyto.2015.05.014
  37. Bleck B, Tse DB, Curotto de Lafaille MA, Zhang F, Reibman J. Diesel exhaust particle-exposed human bronchial epithelial cells induce dendritic cell maturation and polarization via thymic stromal lymphopoietin. J Clin Immunol. 2008 Mar;28(2):147-156. https://doi.org/10.1007/s10875-007-9149-0
  38. Corren J, Parnes JR, Wang L, et al. Tezepelumab in Adults with Uncontrolled Asthma. N Engl J Med. 2017 Sep 7;377(10):936-946. https://doi.org/10.1056/NEJMoa1704064
  39. Emson C, Corren J, Sałapa K, Hellqvist Å, Parnes JR, Colice G. Efficacy of Tezepelumab in Patients with Severe, Uncontrolled Asthma with and without Nasal Polyposis: A Post Hoc Analysis of the Phase 2b PATHWAY Study. J Asthma Allergy. 2021 Feb 3;14:91-99. https://doi.org/10.2147/JAA.S288260
  40. Corren J, Menzies-Gow A, Chupp G, et al. Efficacy of Tezepelumab in Severe, Uncontrolled Asthma: Pooled Analysis of the PATHWAY and NAVIGATOR Clinical Trials. Am J Respir Crit Care Med. 2023 Jul 1;208(1):13-24. https://doi.org/10.1164/rccm.202210-2005OC
slide-cover
slide-cover
slide-cover
slide-cover
Издательство «Медиа Сфера»
РекламаДоставка/ОплатаО насКонтактыОбучение для редакцийПолитика конфиденциальностиПолитика обработки персональных данныхПубличная оферта на реализацию издательской продукции
ЖурналыПодпискаАрхивКнигиПроекты
  • RuStore

© 1998-2026

  • Телефоны издательства:

  • +7 (495) 482-41-18
  • +7 (495) 482-43-29

  • Прямой телефон отдела подписки
    (только по вопросам заказов и доставки журналов)

  • +7 (800) 250-18-12

  • пн-пт с 10:00 до 18:00

  • Telegram
  • VK
info@mediasphera.ru

  • Почтовый адрес:

  • Издательство «Медиа Сфера»,
    а/я 54, Москва, Россия, 127238

  • RuStore

© 1998-2026